Article
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
The New England journal of medicine - 7 Jan 2016
Shaw Alice T, Friboulet Luc, Leshchiner Ignaty, Gainor Justin F, Bergqvist Simon, Brooun Alexei, Burke Benjamin J, Deng Ya-Li, Liu Wei, Dardaei Leila, Frias Rosa L, Schultz Kate R, Logan Jennifer, James Leonard P, Smeal Tod, Timofeevski Sergei, Katayama Ryohei, Iafrate A John, Le Long, McTigue Michele, Getz Gad, Johnson Ted W, Engelman Jeffrey A
Abstract excerpt
In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y). Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.